Comparative Pharmacology
Head-to-head clinical analysis: LAMIVUDINE NEVIRAPINE ZIDOVUDINE TABLETS versus LAMIVUDINE ZIDOVUDINE EFAVIRENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LAMIVUDINE NEVIRAPINE ZIDOVUDINE TABLETS versus LAMIVUDINE ZIDOVUDINE EFAVIRENZ.
LAMIVUDINE/NEVIRAPINE/ZIDOVUDINE TABLETS vs LAMIVUDINE; ZIDOVUDINE; EFAVIRENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase by competing with natural substrates and causing chain termination. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing conformational disruption. Zidovudine is an NRTI that inhibits viral reverse transcriptase after intracellular phosphorylation to its active triphosphate form.
Lamivudine and zidovudine are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit HIV reverse transcriptase by competing with natural substrates and causing chain termination. Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase, causing allosteric inhibition and preventing RNA-dependent DNA polymerization.
One tablet (150 mg lamivudine/200 mg nevirapine/300 mg zidovudine) orally twice daily.
One tablet (lamivudine 300 mg; zidovudine 300 mg; efavirenz 600 mg) orally once daily on an empty stomach, preferably at bedtime.
None Documented
None Documented
Lamivudine: 5-7h (adults), prolonged in renal impairment. Nevirapine: 25-30h (single dose), 40-45h (multiple doses, autoinduction). Zidovudine: 0.5-3h (terminal), prolonged in hepatic impairment.
Lamivudine: 5-7 hours in adults (prolonged in renal impairment). Zidovudine: 0.5-3 hours (terminal half-life), with intracellular active triphosphate half-life ~3 hours. Efavirenz: 40-55 hours (single dose), 10-20 hours at steady state (due to autoinduction), supporting once-daily dosing.
Lamivudine: ~70% renal (glomerular filtration and tubular secretion, unchanged). Nevirapine: ~80% biliary/fecal (metabolites), ~10% renal (unchanged). Zidovudine: ~75% renal (metabolism to glucuronide, tubular secretion).
Lamivudine: renal (approximately 70% unchanged via glomerular filtration and active tubular secretion). Zidovudine: renal (approximately 14% unchanged, major metabolite G-ZDV 60-80% excreted in urine). Efavirenz: hepatic metabolism (CYP2B6, CYP3A4) with fecal (14-34%) and urinary (<1%) elimination.
Category A/B
Category A/B
NRTI
NRTI